NASDAQ | DRNA

$2.79 + 0.06 (+2.198%)

3 month stock price graph

3:59 PM ET on Feb 24, 2017 Pricing delayed 20 minutes

Investors & Media

Management

Image of Douglas M. Fambrough, III, Ph.D.

Doug M. Fambrough, III, Ph.D., has served as a member of our board of directors since April 2007 and as our president and chief executive officer since May 2010. From 2000 to May 2010, Dr. Fambrough held various positions at Oxford Bioscience Partners, a life science venture capital firm, most recently as a general partner. During his years at Oxford Bioscience Partners, he specialized in financing innovative life science technology companies, including the Company, Sirna Therapeutics, Inc. (acquired by Merck & Co., Inc.), Solexa, Inc. (acquired by Illumina, Inc.), and Xencor, Inc. (NASDAQ: XNCR), and served as a director of each of these companies. Dr. Fambrough has also served as a Trustee of Boston Biomedical Research Institute, a not-for-profit organization. Before joining Oxford Bioscience Partners, he was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).

Dr. Fambrough graduated from Cornell University and obtained his Ph.D. in Genetics at the University of California, Berkeley.

Image of Pankaj Bhargava, M.D.

Pankaj Bhargava, M.D. joined us as chief medical officer in March 2014. Prior to that, he was Associate Vice President at Sanofi Oncology from February 2011 to March 2014, where he led the global development of aflibercept (ZALTRAP™) culminating in successful approvals by the U.S. Food and Drug Administration, European Medicines Agency and several other regulatory authorities worldwide. Dr. Bhargava also served as the Gastrointestinal Oncology Therapeutic Leader, Chairman of Protocol Review Committee, and a member of the Development Leadership Team at Sanofi Oncology Division. Prior to joining Sanofi, Dr. Bhargava was Vice President Clinical Research and Interim Chief Medical Officer at AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from November 2006 to February 2011, where he led its clinical programs across all indications spanning from Phase 1 to Phase 3 development and was responsible for clinical and regulatory strategy, clinical development, operations, pharmaco-vigilance and joint development with alliance partners, among other things. Dr. Bhargava currently serves as an Attending Physician at Dana-Farber Cancer Institute and part-time faculty member at Harvard Medical School.

Dr. Bhargava holds an M.B., B.S. degree from the University of Delhi, India, and is an alumnus of Harvard Business School Executive Education Program. Dr. Bhargava is U.S. Board Certified in Internal Medicine, Medical Oncology and Clinical Pharmacology, and did an advanced fellowship in Developmental Therapeutics at the Lombardi Cancer Center, Georgetown University.

Image of Bob D. Brown, Ph.D.

Bob D. Brown, Ph.D. initially served as our senior vice president of research beginning in May 2008 and has served as our chief scientific officer since January 2012. From March 2003 to March 2008, Dr. Brown held various positions at Genta Incorporated, most recently as its vice president of research and technology. Previously, he was a co-founder and vice president of research and development of Oasis Biosciences Inc., which was acquired by Gen-Probe Incorporated. Dr. Brown is an inventor or co-inventor on 16 issued patents and dozens of patent applications covering oligonucleotide and conventional small molecule therapeutic agents, diagnostic tool and oligonucleotide and small molecule drug delivery technologies.

Dr. Brown holds a Ph.D. in molecular biology from the University of California, Berkeley, and a B.S. in chemistry and biology from the University of Washington, Seattle.

Image of Jack Green

Jack Green joined Dicerna as Chief Financial Officer in April 2016. Prior to Dicerna, he was Chief Financial Officer of Verastem, Inc. (VSTM). Previously, Jack served for over 15 years as Chief Financial Officer of GTC Biotherapeutics, Inc. (GTCB; formerly Genzyme Transgenics Corporation), which was spun out from Genzyme Corporation as a stand-alone public company.

Jack is a Certified Public Accountant (CPA) with over 30 years of financial management experience, including 20 within the biotechnology industry. He received a Master’s degree in business administration from Boston University Graduate School of Management and a Bachelor’s degree from the College of the Holy Cross majoring in Economics and Accounting.

Image of Jennifer Lockridge, Ph.D

Jennifer Lockridge, Ph.D., is VP of Program Development at Dicerna Pharmaceuticals and has twenty years of experience in the development of oligonucleotide therapeutics.  She currently oversees development programs at Dicerna and supporting nonclinical activities.  Prior to joining Dicerna, Dr. Lockridge spent nine years consulting with multiple biotech and large pharmaceutical companies to provide direction and support for early development stage oligonucleotide programs as well as pharmacology and pharmacokinetics expertise.  From 1996 to 2007, she was employed at Sirna Therapeutics, Inc. (formerly Ribozyme Pharmaceuticals, Inc.).  As Director of Project Management at Sirna, she managed and was involved with all aspects of siRNA and ribozyme development programs.  Dr. Lockridge received her Ph.D. in pharmacology at the Oregon Health Sciences University, Portland, Oregon and pursued postdoctoral training at the FDA’s National Center for Toxicological Research, Jefferson, Arkansas.

Image of David Miller, Ph.D.

David Miller has successfully combined leadership roles in both business and research capacities. He has been a member of five early stage biotech companies, each of which has successfully transitioned to a public company. Currently, he is Senior Vice President, Corporate Operations at Dicerna Pharmaceuticals, Cambridge, MA, where he has been the past eight years.  At Dicerna, he has also occupied the roles of Vice President of Research Operations and of Business Development.  Dr. Miller was Senior Director, Business Development at Synta Pharmaceuticals, where he had partnering responsibility for their oncology portfolio and played a lead role in a pharma partnership, valued at over $1 billion.  Prior to this, he was Director, Business Development at Altus Biologics where his responsibilities included developing their drug delivery business and the partnering of several biological products.  Dr. Miller was a founder and the head of research for EcoScience Corporation, an agricultural biotechnology company. He began his career at Genetics Institute. Dr. Miller is the inventor on six issued United States patent.  He is a board member of EcoPesticides International, a New Mexico company, and on several public boards in his hometown of Winchester, MA.

Dr. Miller holds a Ph.D. in molecular biology and biochemistry from Harvard University and a B.S. in biochemistry and biophysics from the University of California, Davis.

Image of James B. Weissman

James B. Weissman has served as our chief business officer since January 2012. From January 2006 to January 2012, Mr. Weissman was senior director and then vice president, business development of MannKind Corporation (NASDAQ: MNKD), where he was responsible for leading the company’s activities related to licensing, new products and strategic planning. Prior to MannKind, Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing, responsible for the sales, profit and strategic targets for the company’s specialty products, in a variety of therapeutic areas.

Mr. Weissman holds a B.S. from Bates College in Maine.